- Lobbying
- bluebird AND strategies
Lobbying Arrangements Results for 'Bluebird Strategies'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details FY2025 NCATS research funding FY2025 NCATS funding |
NCATS Alliance
|
BLUEBIRD STRATEGIES | |||
Details H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. |
Luminopia, Inc.
|
BLUEBIRD STRATEGIES | |||
Details Support for S. 723 & H.R. 1458, Access to Prescription Digital Therapeutics Act of 2023: legislation to create CMS reimbursement category for prescription digital therapeutics. |
Bluebird Strategies
|
HOLLAND & KNIGHT LLP | |||
Details Asthma policies and diagnostic allergy test coverage; H.R. 2009 Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 Allergy Testing Access Act of 2019 |
Bluebird Strategies (on behalf of Thermo Fisher Scientific)
|
Faegre Baker Daniels Consulting | |||
Details H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. |
MindMaze Inc.
|
BLUEBIRD STRATEGIES | |||
Details H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. |
Click Therapeutics, Inc.
|
BLUEBIRD STRATEGIES | |||
Details Federal funding for NIH research. |
Faegre Baker Daniels Consulting (on behalf of Global Down Syndrome Foundation)
|
BLUEBIRD STRATEGIES | |||
Details Asthma policies and diagnostic allergy test coverage; H.R. 2009 - Removing Barriers to Allergy Diagnostic Testing Act of 2019; S. 2246 - Allergy Testing Access Act of 2019 |
Bluebird Strategies (on behalf of Thermo Fisher Scientific)
|
Faegre Drinker Biddle & Reath LLP | |||
Details H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. |
Otsuka America Pharmaceutical, Inc.
|
BLUEBIRD STRATEGIES | |||
Details CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PAS... |
The Peggy Lillis Foundation
|
BLUEBIRD STRATEGIES | |||
Details Legislation to regulate clinical labs under CLIA and FDA. Medicaid coverage for mental health genetic testing. VA access for mental health genetic testing. Medicaid precision medicine legislation. |
Myriad Genetics, Inc.
|
BLUEBIRD STRATEGIES | |||
Details Increasing funding for Myotonic Dystrophy research. Fiscal Year 2024 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program. Fe... |
Myotonic
|
BLUEBIRD STRATEGIES | |||
Details Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. Medicare/Medicaid coverage report language. Mental health prescription digital therapeutics coverage. |
Pear Therapeutics
|
BLUEBIRD STRATEGIES | |||
Details H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics. |
Boehringer Ingelheim USA Corporation
|
BLUEBIRD STRATEGIES | |||
Details Federal funding for NIH research. |
Global Down Syndrome Foundation
|
BLUEBIRD STRATEGIES | |||
Details Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics. Iss... |
Thermo Fisher Scientific Inc.
|
BLUEBIRD STRATEGIES |